Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229951 | 0.88 | NPC1 (0.47) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL179869 | 0.82 | NPC1 (0.44) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL5317101 | 0.80 | — | — | |
| SCHEMBL6765328 | 0.79 | NPC1 (0.42) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL28554259 | 0.78 | NPC1 (0.44) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL34651 | 0.77 | — | — | |
| SCHEMBL29014453 | 0.77 | NPC1 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL28891107 | 0.77 | NPC1 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL6270339 | 0.76 | — | — | |
| SCHEMBL262815 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331277-B2 | H2O2-responsive nanoparticles and uses thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20190125891-A1 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR | TRANSTARGET INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017118690-A1 | A NOVEL SYNTHETIC PATHWAY TOWARDS SOLITHROMYCIN AND PURIFICATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2017-07-13 | — | — | WO | disclosed |
| EP-3190122-A1 | A NOVEL SYNTHETIC PATHWAY TOWARDS SOLITHROMYCIN AND PURIFICATION THEREOF | LEK Pharmaceuticals d.d. (SI) | 2017-07-12 | — | — | EP | disclosed |
| US-20170035902-A1 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR | TRANSTARGET INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9499619-B2 | Polyclonal bispecific antibody compositions and method of use | TRANSTARGET, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160003841-A1 | INTEGRATED HIGH THROUGHPUT SYSTEM FOR THE ANALYSIS OF BIOMOLECULES | INTRINSIC BIOPROBES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9134306-B2 | Integrated high throughput system for the analysis of biomolecules | INTRINSIC BIOPROBES, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150175700-A1 | POLYCLONAL BISPECIFIC ANTIBODY COMPOSITIONS AND METHOD OF USE | TRANSTARGET, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150104478-A1 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR | TRANSTARGET INC (US) | 2015-04-16 | — | — | US | disclosed |
| US-6319674-B1 | IMMOBILIZATION ON SURFACE WITH AMINES AND HYDROXY GROUPS | AGILENT TECHNOLOGIES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6177572-B1 | 2-AMIDOPHENOL OR 2-AMIDOTHIOPHENOL IS COUPLED TO A SOLID PHASE SUPPORT THROUGH A LINKER GROUP, SUCH THAT A BENZOXAZOLE OR A BENZOTHIAZOLE IS FORMED | SEPRACOR, INC. | 2001-01-23 | — | — | US | disclosed |
| EP-1007518-A1 | SOLID AND LIQUID-PHASE SYNTHESIS OF BENZOXAZOLES AND BENZOTHIAZOLES AND THEIR USE | SEPRACOR, INC. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999009017-A1 | SOLID AND LIQUID-PHASE SYNTHESIS OF BENZOXAZOLES AND BENZOTHIAZOLES AND THEIR USE | SEPRACOR INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0607327-B1 | COVALENTLY REACTIVE PARTICLES INCORPORATED IN A CONTINUOUS POROUS MATRIX | MINNESOTA MINING & MFG (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5700642-A | HYBRIDIZING PRIMER WITH COMPLEMENTARY TARGET NUCLEIC ACID, ENZYMATICALLY EXTENDING PRIMER TO GENERATE POLYNUCLEOTIDE MIXTURE, IMMOBILIZATION, CLEAVING TO RELEASE EXTENSION SEGMENT AND MEASUREMENT BY MASS SPECTROMETRY | SRI INTERNATIONAL (US) | 1997-12-23 | — | — | US | disclosed |
| US-5506262-A | ANTICHOLESTEROL AGENTS, FUNGICIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-5045201-A | Glass microbeads for biochemical separation of material from a fluid medium | GLAVERBEL (BE) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331277-B2 | H2O2-responsive nanoparticles and uses thereof | GPX4, G6PD, HAO2 | NPC1 4112/4885RAB9A 2762/4885KMT2A 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.